EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
GlaxoSmithKline (United Kingdom) · GlaxoSmithKline (United States)
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,785
total citations
- FWCI
- 68.38
- Percentile
- 100%
- References
- 31
Citations per year
Authors
22- MTMichael T. McCabeCorresponding
GlaxoSmithKline (United Kingdom)
- HMHeidi M. Ott
GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States)
- GGGopinath Ganji
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
- SKSusan Korenchuk
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
- CTChristine Thompson
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
Topics & keywords
Topics
Keywords
- EZH2
- PRC2
- Histone methyltransferase
- Cancer research
- Histone H3
- Biology
- Germinal center
- Chromatin
No related works found for this paper.